Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC).

View Full Paper
Ask AI
Bookmark
Share

Authors

SBStacey DaCosta ByfieldBBBela BapatLBLaura Becker

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Byfield et al. (2024) studied this question.

synapsesocial.com/papers/68e66dd2b6db6435875f93cahttps://doi.org/10.1200/jco.2024.42.16_suppl.e20598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC).2024 · 2 citations
  2. 2Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices2026
  3. 3Real-world adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.2026
  4. 4Biomarker testing and targeted therapy use among patients with non-small cell lung cancer in the United States: An analysis using a physician notes real-world database.2024
  5. 5Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer.2024